SEC Form 4 · accession 0000886163-18-000089
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew E Korenberg
Officer — EVP,Finance & Strategy and CFO
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 3:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | J | 180 | $117.8355 | A | 14,395 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).